EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer
2018 | journal article
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer
Semmlinger, A.; von Schoenfeldt, V.; Wolf, V.; Meuter, A.; Kolben, T. M.; Kolben, T. & Zeder-Goess, C. et al. (2018)
BMC Cancer, 18(1) pp. 431. DOI: https://doi.org/10.1186/s12885-018-4286-9
Documents & Media
Details
- Authors
- Semmlinger, Anna; von Schoenfeldt, Viktoria; Wolf, Verena; Meuter, Alexandra; Kolben, Theresa Maria; Kolben, Thomas; Zeder-Goess, Christine; Weis, Florian; Gallwas, Julia ; Wuerstlein, Rachel; Hermelink, Kerstin; Schmoeckel, Elisa; Harbeck, Nadia; Mayr, Doris; Mahner, Sven; Jeschke, Udo; Ditsch, Nina
- Abstract
- In various cancers, overexpression of cyclooxygenase (COX)-2 and elevated prostaglandin (PG) E2 synthesis have been associated with tumor development and progression. The potential of COX-2 inhibitors in cancer prevention and treatment has been shown repeatedly; however, their clinical use is limited due to toxicity. PGE2 signals via EP receptors 1-4, whose functions are analyzed in current research in search for targeted anti-PG therapies. EP2 and EP4 rather promote tumorigenesis, while the role of EP3, especially in breast cancer, is not yet clear and both pro- and anti-tumorigenic effects have been described. Our study evaluates EP3 receptor expression in sporadic breast cancer and its association with clinicopathological parameters, progression-free and overall survival.
- Issue Date
- 2018
- Journal
- BMC Cancer
- ISSN
- 1471-2407
- Language
- English